Professor Philip G Ashton-Rickardt

Publications


Journals

  • Choi O; Heathcote DA; Ho KK; Müller PJ; Ghani H; Lam EW; Ashton-Rickardt PG; Rutschmann S. (15 Apr 2012). A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival. J Immunol. 188:3920-3927. DOI.
  • Lovo E; Zhang M; Wang L; Ashton-Rickardt PG. (1 Feb 2012). Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol. 188:1057-1063. DOI.
  • Ashton-Rickardt PG; Van Kaer L; Schumacher TN; Ploegh HL; Tonegawa S. (4 Jun 1993). Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell. 73:1041-1049.
  • Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Ploegh HL. (Jan 1995). Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice. Eur J Immunol. 25:174-178. DOI.
  • Oxenius A; Bachmann MF; Ashton-Rickardt PG; Tonegawa S; Zinkernagel RM; Hengartner H. (Dec 1995). Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol. 25:3402-3411. DOI.
  • Van Kaer L; Ashton-Rickardt PG; Eichelberger M; Gaczynska M; Nagashima K; Rock KL; Goldberg AL; Doherty PC; et alTonegawa S. (Oct 1994). Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity. 1:533-541.
  • Shepherd JC; Schumacher TN; Ashton-Rickardt PG; Imaeda S; Ploegh HL; Janeway CA; Tonegawa S. (13 Aug 1993). TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell. 74:577-584.
  • Murray K; Stahl S; Ashton-Rickardt PG. (31 Aug 1989). Genetic engineering applied to the development of vaccines. Philos Trans R Soc Lond B Biol Sci. 324:461-476.
  • Ashton-Rickardt PG. (Sep 1993). The role of peptide in the positive selection of CD8+ T cells in the thymus. Thymus. 22:111-115.
  • Ashton-Rickardt PG; Dunlop MG; Nakamura Y; Morris RG; Purdie CA; Steel CM; Evans HJ; Bird CC; et alWyllie AH. (Oct 1989). High frequency of APC loss in sporadic colorectal carcinoma due to breaks clustered in 5q21-22. Oncogene. 4:1169-1174.
  • Ashton-Rickardt PG; Bandeira A; Delaney JR; Van Kaer L; Pircher HP; Zinkernagel RM; Tonegawa S. (25 Feb 1994). Evidence for a differential avidity model of T cell selection in the thymus. Cell. 76:651-663.
  • Hu Q; Bazemore Walker CR; Girao C; Opferman JT; Sun J; Shabanowitz J; Hunt DF; Ashton-Rickardt PG. (Aug 1997). Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. Immunity. 7:221-231.
  • Aldrich CJ; Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Forman J. (5 Jul 1994). Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice. Proc Natl Acad Sci U S A. 91:6525-6528.
  • Ashton-Rickardt PG; Tonegawa S. (Aug 1994). A differential-avidity model for T-cell selection. Immunol Today. 15:362-366.
  • Ashton-Rickardt PG; Van Kaer L; Schumacher TN; Ploegh HL; Tonegawa S. (Oct 1993). Repertoire-determining role of peptide in the positive selection of CD8+ T cells. Immunol Rev. 135:157-182.
  • Ashton-Rickardt PG; Murray K. (Nov 1989). Mutations that change the immunological subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determination. J Med Virol. 29:204-214.
  • Ashton-Rickardt PG. (2007). Studying T-cell repertoire selection using fetal thymus organ culture. Methods Mol Biol. 380:171-184.
  • Ashton-Rickardt PG; Wyllie AH; Bird CC; Dunlop MG; Steel CM; Morris RG; Piris J; Romanowski P; et alWood R; White R. (Oct 1991). MCC, a candidate familial polyposis gene in 5q.21, shows frequent allele loss in colorectal and lung cancer. Oncogene. 6:1881-1886.
  • Ashton-Rickardt, P.G (2009. Ashton-Rickardt, P.G (2009 (ed). (2009). Serine Protease Inhibitors and T Lymphocyte Immunity. Current Immunol. Rev. 25 3:187-199(13).
  • Ashton-Rickardt, P.G. (2007). (2007). Studying T cell repertoire selection using fetal thymus organ cultures. From: Methods in Molecular Biology, vol. 380: Immunological Tolerance: Methods and Protocols. Edited by: P.J. Fairchild. Humana Press Inc. Totawa, NJ: 10:171-184.
  • Hu, Q., Bazemore Walker, C.R., Girao, C., Opferman, J.T., Sun, J., Shabanowitz, J., Hunt, D.F., and Ashton-Rickardt, P.G. (1997. Hu, Q., Bazemore Walker, C.R., Girao, C., Opferman, J.T., Sun, J., Shabanowitz, J., Hunt, D.F., and Ashton-Rickardt, P.G. (1997 (ed). (1997). Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. Immunity 7: 221-231.
  • Oxenius, A., Bachmann, M.E., Ashton-Rickardt, P.G., Tonegawa, S., Zinkernagel, R.M., and Hengartner, H. (1995. Oxenius, A., Bachmann, M.E., Ashton-Rickardt, P.G., Tonegawa, S., Zinkernagel, R.M., and Hengartner, H. (1995 (ed). (1995). Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur. J. Immunol. 25:3402-3411.
  • 19. Bachmann, M.F., Oxenius, A., Pircher, H., Hengartner, H., Ashton-Rickardt, P.G., Tonegawa, S., and Zinkernagel, R.M. (1995. 19. Bachmann, M.F., Oxenius, A., Pircher, H., Hengartner, H., Ashton-Rickardt, P.G., Tonegawa, S., and Zinkernagel, R.M. (1995 (ed). (1995). ). TAP-1 independent loading of class I molecules by exogenous viral proteins. Eur. J. Immunol. 25:1739-1743.
  • Ljunggren, H-G., Van Kaer, L., Ashton-Rickardt, P.G., Tonegawa, S., and Ploegh H.L. (1995).. Ljunggren, H-G., Van Kaer, L., Ashton-Rickardt, P.G., Tonegawa, S., and Ploegh H.L. (1995). (ed). (1995). Differential reactivity of residual CD8+ T lymphocytes in TAP1 and 2-microglobulin mutant mice. Eur. J . Immunol . 25:174-178.
  • 17. Martien van Santen, H., Woolsey, A., Ashton-Rickardt, P.G., Van Kaer, L., Baas, E-J., Berns, A., Tonegawa, S., and Ploegh, H.L. (1995). 17. Martien van Santen, H., Woolsey, A., Ashton-Rickardt, P.G., Van Kaer, L., Baas, E-J., Berns, A., Tonegawa, S., and Ploegh, H.L. (1995) (ed). (1995). Increase in positive selection of CD8+ T cells in TAP1-mutant mice by human 2-microglobulin transgene. J. Exp. Med 181:787-792.
  • Van Kaer, L.,* Ashton-Rickardt, P.G*., Eichelberger, M., Gaczynska, M., Nagashima, K., Rock, K., Goldberg, A., Doherty, P.C., and Tonegawa, S. (1994).. Van Kaer, L.,* Ashton-Rickardt, P.G*., Eichelberger, M., Gaczynska, M., Nagashima, K., Rock, K., Goldberg, A., Doherty, P.C., and Tonegawa, S. (1994). (ed). (1994). Altered peptidase activity, antigen processing and antiviral activity in LMP-2 mutant mice. Immunity 1:533-541.*co-1st author.
  • Aldrich. C.J., Ljunggren, H-G., Van Kaer. L., Ashton-Rickardt P.G., Tonegawa S., and Forman, J. (1994).. Aldrich. C.J., Ljunggren, H-G., Van Kaer. L., Ashton-Rickardt P.G., Tonegawa S., and Forman, J. (1994). (ed). (1994). Positive selection of self-and allo-reactive CD8+ T cells in TAP-1 mutant mice. Proc. Natl. Acad. Sci. USA 91:6525-6528.
  • Ashton-Rickardt, P.G., and Tonegawa, S. (1994. Ashton-Rickardt, P.G., and Tonegawa, S. (1994 (ed). (1994). A differential avidity model of T cell selection. Immunol. Today 15:362-366.
  • Ashton-Rickardt, P.G., Bandeira. A., Delaney, J.R, Van Kaer, L., Pircher, H-P., Zinkernagel, R.M., and Tonegawa, S. (1994).. Ashton-Rickardt, P.G., Bandeira. A., Delaney, J.R, Van Kaer, L., Pircher, H-P., Zinkernagel, R.M., and Tonegawa, S. (1994). (ed). (1994). Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651-663.
  • Ashton-Rickardt, P.G. (1993).. Ashton-Rickardt, P.G. (1993). (ed). (1993). The role of Peptide in the Positive Selection of CD8+ T cells in the thymus. Thymus 22: 111-115.
  • Ashton-Rickardt, P.G., Van Kaer, L., Schumacher, T.H.M., Ploegh, H.L., and Tonegawa, S. (1993).. Ashton-Rickardt, P.G., Van Kaer, L., Schumacher, T.H.M., Ploegh, H.L., and Tonegawa, S. (1993). (ed). (1993). Repertoire determining role of peptide in the positive selection of CD8+ T cells. Immunol. Rev. 35:157-182.
  • Shepherd, J.C, Schumacher, T.N.M. Ashton-Rickardt, P.G., Imaeda, S., Ploegh, H.L., Janeway, C.A., and Tonegawa, S. (1993).. Shepherd, J.C, Schumacher, T.N.M. Ashton-Rickardt, P.G., Imaeda, S., Ploegh, H.L., Janeway, C.A., and Tonegawa, S. (1993). (ed). (1993). TAP-1 dependent peptide translocation in vitro is ATP-dependent and peptide selective. Cell 74:577-584.
  • Ashton-Rickardt, P.G., Van Kaer, L., Schumacher, T.N.M., Ploegh, H.L., and Tonegawa, S. (1993). Ashton-Rickardt, P.G., Van Kaer, L., Schumacher, T.N.M., Ploegh, H.L., and Tonegawa, S. (1993) (ed). (1993). Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell 73:1041-1049.
  • Ashton-Rickardt, P.G., Wyllie, A.H., Bird, C.C., Dunlop, M.G., Steel, C.M., Morris, R.G., Piris, J., Romoanowski, P., Wood, R., White, R. and Nakamura, Y.. Ashton-Rickardt, P.G., Wyllie, A.H., Bird, C.C., Dunlop, M.G., Steel, C.M., Morris, R.G., Piris, J., Romoanowski, P., Wood, R., White, R. and Nakamura, Y. (ed). (1991). MCC, A candidate familial polyposis gene in 5q21, shows frequent allele loss in colorectal and lung cancer. Oncogene 6:1881-1886.
  • 5. Ashton-Rickardt, P.G., Dunlop, M.G., Nakamura, Y., Morris, R.G., Purdie, C.A., Steel, C.M., Evans, H.J., Bird, C.C., Wyllie, A.H. (1989).. Ashton-Rickardt, p.G. (ed). (1989). Sporadic colorectal tumours show a high degree of APC loss due to breakpoints clustered in 5q21-22. Oncogene 4:1169-1174.
  • Murray, K., Stahl. S., Ashton-Rickardt, P.G.. Murray, K. (ed). (1989). Murray, K., Stahl, S., Ashton-Rickardt, P.G. (1989). Immunization against Hepatitis B virus. Cur.Topics Med.Virol., March.
  • Murray,K. , Stahl. S., Ashton-Rickardt, P.G.. Murray, K. Stahl (ed). (1989). 3. PMID:2573084 Murray, K., Stahl, S., Ashton-Rickardt, P.G. (1989). Genetic engineering applied to the development of vaccines. Phil. Trans. R . Soc. Lond. B. 324 :461-476.
  • Ashton-Rickardt, P.G., and Murray, K.. (1989). 1. PMID:2693610 Ashton-Rickardt, P.G., and Murray, K. (1989). Mutants of Hepatitis B Virus Surface Antigen which define antigenically essential residues. J. Med. Virol. 29:196-203.
  • Park S-M; Chen L; Zhang M; Ashton-Rickardt P; Turner JR; Peter ME. (1 Jun 2010). CD95 Is Cytoprotective for Intestinal Epithelial Cells in Colitis. INFLAMMATORY BOWEL DISEASES. 16:1063-1070. Author weblink DOI.
  • Ober BT; Hu QH; Opferman JT; Hagevik S; Chiu N; Wang CR; Ashton-Rickardt PG. (1 Sep 2000). Affinity of thymic self-peptides for the TCR determines the selection of CD8(+) T lymphocytes in the thymus. INTERNATIONAL IMMUNOLOGY. 12:1353-1363. Author weblink DOI.
  • Opferman JT; Ober BT; Narayanan R; Ashton-Rickardt PG. (1 Apr 2001). Suicide induced by cytolytic activity controls the differentiation of memory CD8(+) T lymphocytes. INTERNATIONAL IMMUNOLOGY. 13:411-419. Author weblink DOI.
  • Schumacher TN; Kantesaria DV; Heemels MT; Ashton-Rickardt PG; Shepherd JC; Fruh K; Yang Y; Peterson PA; et alTonegawa S; Ploegh HL. (1 Feb 1994). Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med. 179:533-540.
  • Van Kaer L; Ashton-Rickardt PG; Ploegh HL; Tonegawa S. (24 Dec 1992). TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell. 71:1205-1214.
  • Ashton-Rickardt PG; Murray K. (Nov 1989). Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol. 29:196-203.
  • Girao C; Hu QH; Sun JL; Ashton-Rickardt PG. (1 Nov 1997). Limits to the differential avidity model of T cell selection in the thymus. JOURNAL OF IMMUNOLOGY. 159:4205-4211. Author weblink.
  • Markiewicz MA; Girao C; Opferman JT; Sun JL; Hu QH; Agulnik AA; Bishop CE; Thompson CB; et alAshton-Rickardt PG. (17 Mar 1998). Long-term T cell memory requires the surface expression of self-peptide major histocompatibility complex molecules. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 95:3065-3070. Author weblink DOI.
  • Opferman JT; Ober BT; Ashton-Rickardt PG. (12 Mar 1999). Linear differentiation of cytotoxic effectors into memory T lymphocytes. SCIENCE. 283:1745-1748. Author weblink DOI.
  • Ashton-Rickardt PG; Opferman JT. (1 Oct 1999). Memory T lymphocytes. CELLULAR AND MOLECULAR LIFE SCIENCES. 56:69-77. Author weblink DOI.
  • El Haddad N; Moore R; Heathcote D; Mounayar M; Azzi J; Mfarrej B; Batal I; Ting C; et alAtkinson M; Sayegh MH; Ashton-Rickardt PG; Abdi R. (1 Sep 2011). The Novel Role of SERPINB9 in Cytotoxic Protection of Human Mesenchymal Stem Cells. JOURNAL OF IMMUNOLOGY. 187:2252-2260. Author weblink DOI.
  • El Haddad N; Heathcote D; Moore R; Yang S; Azzi J; Mfarrej B; Atkinson M; Sayegh MH; et alLee J-S; Ashton-Rickardt PG; Abdi R. (27 Jan 2011). Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. BLOOD. 117:1176-1183. Author weblink DOI.
  • Akiyoshi T; Heathcote DA; Azzi J; Zhang M; Rodig SJ; El-Haddad N; Yang S; Moore RF; et alSayegh MH; Ashton-Rickardt PG; Abdi R. (1 Apr 2010). The Role of SPI6 in the Survival of Allograft Derived Dendritic Cells and Tolerance. AMERICAN JOURNAL OF TRANSPLANTATION. 10:561-561.
  • Ansari AW; Temblay JN; Alyahya SH; Ashton-Rickardt PG. (15 Jul 2010). Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage. J Immunol. 185:877-883. DOI.
  • Ashton-Rickardt PG. (1 May 2010). Serine protease inhibitors and cytotoxic T lymphocytes. IMMUNOLOGICAL REVIEWS. 235:147-158. Author weblink.
  • Park S-M; Rajapaksha TW; Zhang M; Sattar HA; Fichera A; Ashton-Rickardt PG; Peter ME. (1 Jan 2008). CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. APOPTOSIS. 13:41-51. Author weblink DOI.
  • Zhang M; Liu N; Park S-M; Wang Y; Byrne S; Murmann AE; Bahr S; Peter ME; et alOlson ST; Belaaouaj A; Ashton-Rickardt PG. (1 Oct 2007). Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa. JOURNAL OF IMMUNOLOGY. 179:4390-4396. Author weblink.
  • Zhang, M; Park, SM; Wang, Y; Shah, R; Liu, N; Murmann, AE; Wang, CR; Peter, ME; et alAshton-Rickardt, PG. (2006). Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity. 4, 24:451-461. Author weblink.
  • Liu, N; Phillips, T; Zhang, M; Wang, Y; Opferman, JT; Shah, R; Ashton-Rickardt, PG. (1 Sep 2004). Serine protease inhibitor 2A is a protective factor for memory T cell development. Nature Immunology. 9, 5:919-926. Author weblink.
  • Phillips, T P; Opferman, J T; Shah, R; Liu, N; Froelich, C J; Ashton-Rickardt, P G. (2004). A role for the granzyme B inhibitor serine protease inhibitor 6 in CD8(+) memory cell homeostasis. Journal of Immunology. 6, 173:3801-3809. Author weblink.
  • Zhang M; Byrne S; Liu N; Wang Y; Oxenius A; Ashton-Rickardt PG. (15 Mar 2007). Differential survival of cytotoxic T cells and memory cell precursors. JOURNAL OF IMMUNOLOGY. 178:3483-3491. Author weblink.
  • Hirst CE; Buzza MS; Bird CH; Warren HS; Cameron PU; Zhang ML; Ashton-Rickardt PG; Bird PI. (15 Jan 2003). The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. JOURNAL OF IMMUNOLOGY. 170:805-815. Author weblink.
  • Hettmann T; Opferman JT; Leiden JM; Ashton-Rickardt PG. (3 Feb 2003). A critical role for NF-kappa B transcription factors in the development of CD8(+) memory-phenotype T cells. IMMUNOLOGY LETTERS. 85:297-300. Author weblink DOI.
  • Liu N; Wang Y; Ashton-Rickardt PG. (2 Jul 2004). Serine protease inhibitor 2A inhibits caspase-independent cell death. FEBS LETTERS. 569:49-53. Author weblink DOI.
  • Ashton-Rickardt PG. (1 Nov 2004). A license to remember. NATURE IMMUNOLOGY. 5:1097-1098. Author weblink DOI.
  • Ashton-Rickardt PG. (1 Jan 2005). The granule pathway of programmed cell death. CRITICAL REVIEWS IN IMMUNOLOGY. 25:161-182. Author weblink DOI.

Conferences

  • Lovo E; Zhang M; Ashton-Rickardt PG. Serine protease inhibitor-6 (Spi6) is required for dendritic cell priming of anti-viral CD8 T cell responses through protection from granzyme B. Annual Congress of the British-Society-for-Immunology, 5 Dec 2011 - 8 Dec 2011. 135:133-133. WILEY-BLACKWELL (1 Dec 2011).
  • Thompson CB; Rathmell JC; Frauwirth KA; Lindsten T; Rudin CM; Opferman JT; Ashton-Rickardt PG; Harris MH; et alChandel NS; Schumacker PT; Vander Heiden MG. What keeps a resting T cell alive?. 64th Symposia: Signaling and Gene Expression in the Immune System, 2 Jun 1999 - 7 Jun 1999. 64:383-387. COLD SPRING HARBOR LAB PRESS (1 Jan 1999). Author weblink DOI.
  • El Haddad NM; Heathcote D; Lee J-S; Augello A; Akiyoshi T; Azzi J; Mfarrej B; Yang S; et alMoore R; Sayegh M; Ashton-Rickardt P; Abdi R. Mesenchymal Stem Cells Require Serpin Protease Inhibitor 6 (SPI6) To Evade Allogeneic Cytotoxic T-Lymphocytes. 70th Annual Meeting of the American-Diabetes-Association, 25 Jun 2010 - 29 Jun 2010. 59:A44-A44. AMER DIABETES ASSOC (1 Jun 2010). Author weblink.
  • Dev A; Fang J; McCrann D; Emerson C; Pradeep A; Browne S; Ashton-Rickardt P; Wojchowski DM. Non-Redundant Roles for an Epo/EpoR/STAT5 Regulated Intracellular Serpin, Serpina-3G, during Epo- and Anemia- Induced Erythropoiesis. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:329-329. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
  • Akiyoshi T; Heathcote DA; Azzi J; Batal I; Zhang M; Rodig SJ; El-Haddad N; Yang S; et alMoore RF; Ting C; Sayegh MH; Ashton-Rickardt PG; Abdi R. The Role of SPI6 in the Survival of Allograft Derived Dendritic Cells. American Transplant Congress, 2011. 11:218-218. WILEY-BLACKWELL (1 Apr 2011). Author weblink.
  • Liu N; Raja SM; Zazzeroni F; Shah R; Wang Y; Zhang ML; Bromme D; Froelich CJ; et alFranzozso G; Ashton-Rickardt PG. Induction of a cathepsin B inhibitor by NF-kB blocks the lysosomal pathway of cell death. 90th Annual Meeting of the American-Association-for-Immunologists, 6 May 2003 - 10 May 2003. 17:C152-C152. FEDERATION AMER SOC EXP BIOL (14 Apr 2003). Author weblink.

Patents

  • Methods and compositions for the inhibition of cathepsins, US 2009/0324700 A1. Published: 2009.
  • Induction of Immunity using inhibitors of granzymes, US 2003/0148511 A1. Patent number: US 2003/0148511 A1. Published: 2003.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook